Literature DB >> 2809583

Dietary supplementation of tyrosine prevents the rapid fall in blood pressure during haemorrhage.

F A Moya-Huff1, J M Pinto, P J Kiritsy, T J Maher.   

Abstract

Previous studies have demonstrated the ability of tyrosine (TYR), the amino acid precursor of catecholamines, to increase blood pressure in rats made hypotensive by haemorrhage. Other studies have shown that supplementation of the diet with TYR can reverse certain neurochemical and behavioural consequences associated with acute stress. Such studies demonstrate that during conditions of enhanced neuronal firing catecholamine synthesis is accelerated when additional precursor TYR is made available. In these situations the rate-limiting enzyme of catecholamine synthesis, tyrosine hydroxylase, activated via phosphorylation, becomes responsive to additional TYR. Our experiments were designed to study the ability of dietary TYR (3.7%, or 4X the normal amount), to prevent the rapid fall in blood pressure observed during acute haemorrhage. Rats consuming the high TYR diet (5 days) maintained arterial blood pressure (systolic, diastolic and mean) at significantly greater values during the period of acute haemorrhagic insult than animals maintained on a control diet. Rats fed the high TYR diet had significantly greater levels of the amino acid in the heart, adrenal glands, liver, kidney, brainstem, spleen and semimembranosus pars caudalis muscle. We conclude that TYR can be stored and most likely utilized in the synthesis of catecholamines for the maintenance of arterial blood pressure during acute haemorrhage. These results are of particular importance in light of the fact that most total parenteral nutrition solutions contain very little if any TYR.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2809583     DOI: 10.1007/bf01252501

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  21 in total

1.  ATP, cyclic AMP, and magnesium increase the affinity of rat striatal tyrosine hydroxylase for its cofactor.

Authors:  W Lovenberg; E A Bruckwick; I Hanbauer
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

2.  The action of 1-tyrosine and arachidonic acid on the experimental hypertension in rat: physiopathogenic deductions.

Authors:  H Laborit; N Valette
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1974-07

Review 3.  Role of the sympathetic nervous system in hemorrhage.

Authors:  S Chien
Journal:  Physiol Rev       Date:  1967-04       Impact factor: 37.312

4.  Tyrosine administration decreases serum prolactin levels in chronically reserpinized rats.

Authors:  A F Sved; J D Fernstrom; R J Wurtman
Journal:  Life Sci       Date:  1979-10-08       Impact factor: 5.037

5.  Tyrosine administration enhances dopamine synthesis and release in light-activated rat retina.

Authors:  C J Gibson; C J Watkins; R J Wurtman
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

6.  Tyrosine accelerates catecholamine synthesis in hemorrhaged hypotensive rats.

Authors:  L A Conlay; T J Maher; R J Wurtman
Journal:  Brain Res       Date:  1985-04-29       Impact factor: 3.252

7.  Tyrosine's vasoactive effect in the dog shock model depends on the animal's starting blood pressure.

Authors:  L A Conlay; T J Maher; P L Moses; R J Wurtman
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

8.  Behavioural and biochemical effects of tryptophan, tyrosine and phenylalanine in mice.

Authors:  C J Gibson; S M Deikel; S N Young; Y M Binik
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  On the patterns of blood pressure, heart rate, and blood levels of noradrenaline and adrenaline during haemorrhage in the rat.

Authors:  J Häggendal
Journal:  Acta Physiol Scand       Date:  1986-08

10.  Effect of tyrosine administration on dopa accumulation in light- and dark-adapted retinas from normal and diabetic rats.

Authors:  M H Fernstrom; E A Volk; J D Fernstrom; P M Iuvone
Journal:  Life Sci       Date:  1986-12-01       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.